適用於與Rilpivirine注射劑併用，治療已達病毒學抑制效果（HIV-1 RNA < 50 copies/mL）且對Cabotegravir及Rilpivirine無已知或疑似抗藥性之成人的HIV-1感染。
Indicated for use in combination with Rilpivirine injection to treat HIV-1 infection in adults who have achieved viral suppression (HIV-1 RNA < 50 copies/mL) and have no known or suspected resistance to Cabotegravir and Rilpivirine.
Cabotegravir 為 HIV 嵌合合抑制劑，藉由與嵌合合的活性部位結合，阻斷反轉錄病毒 DNA 嵌合的鏈轉移步驟，抑制病毒複製。
Cabotegravir is an HIV integrase inhibitor that binds to the active site of the enzyme, blocking the strand transfer step of retroviral DNA integration and inhibiting viral replication.
吸收：Cabotegravir 在肌肉注射後緩慢吸收，於 7 天達到最高血漿濃度，並可維持超過 12 個月。
分布：與血漿蛋白高度結合（>99%），並分布於生殖道及腦脊髓液中。
代謝：主要經由 UGT1A1 代謝，少部分經由 UGT1A9。
排除：主要經由糞便排出（47%），少量經由尿液排除。
Absorption: Slowly absorbed after intramuscular injection, reaching peak plasma concentration at 7 days, and can persist for more than 12 months.
Distribution: Highly bound to plasma proteins (>99%) and distributed to reproductive tissues and cerebrospinal fluid.
Metabolism: Primarily metabolized by UGT1A1, with minor involvement of UGT1A9.
Excretion: Mainly excreted in feces (47%), with a small amount in urine.
對Cabotegravir或任何賦形劑過敏者禁用。禁忌與Rifampicin、Rifapentine、Carbamazepine、Oxcarbazepine、Phenytoin、Phenobarbital併用。
Contraindicated in patients with hypersensitivity to Cabotegravir or any excipients. Concomitant use with Rifampicin, Rifapentine, Carbamazepine, Oxcarbazepine, Phenytoin, or Phenobarbital is contraindicated.
懷孕期間不建議使用Cabotegravir，除非預期效益超越胎兒可能的風險。動物研究顯示高劑量可能對生殖造成影響。
Cabotegravir is not recommended during pregnancy unless the potential benefits outweigh the risks to the fetus. Animal studies have shown reproductive toxicity at high doses.
Cabotegravir 可能會分泌至人類乳汁，建議感染 HIV 的婦女避免哺乳以防止病毒傳染。
Cabotegravir may be excreted in human milk. Women with HIV infection are advised not to breastfeed to prevent HIV transmission.
極常見：注射部位反應、頭痛、發燒。
常見：頭暈、噁心、皮疹、肌痛。
極少見：過敏反應、肝毒性、血管迷走神經反應。
Very Common: Injection site reactions, headache, fever.
Common: Dizziness, nausea, rash, myalgia.
Rare: Hypersensitivity reactions, hepatotoxicity, vasovagal reactions.
起始劑量：600 mg IM，每月一次。
後續劑量：每月 400 mg IM 或每兩個月 600 mg IM。
Initial Dose: 600 mg IM once a month.
Maintenance Dose: 400 mg IM monthly or 600 mg IM every two months.
18 歲以下兒童及青少年的安全性與療效尚未確立。
Safety and efficacy in children and adolescents under 18 years of age have not been established.
輕至重度腎功能不全者無需調整劑量，但末期腎病患者需謹慎使用。
No dose adjustment is required for mild to severe renal impairment. Use cautiously in end-stage renal disease.
輕至中度肝功能不全者無需調整劑量，但重度肝功能不全患者不建議使用。
No dose adjustment is required for mild to moderate hepatic impairment. Not recommended for severe hepatic impairment.